Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Great hopes have been placed on human pluripotent stem (hPS) cells for therapy. Tissues or organs derived from hPS cells could be the best solution to cure many different human diseases, especially those who do not respond to standard medication or drugs, such as neurodegenerative diseases, heart failure, or diabetes. The origin of hPS is critical and the idea of creating a bank of well-characterized hPS cells has emerged, like the one that already exists for cord blood. However, the main obstacle in transplantation is the rejection of tissues or organ by the receiver, due to the three main immunological barriers: the human leukocyte antigen (HLA), the ABO blood group, and minor antigens. The problem could be circumvented by using autologous stem cells, like induced pluripotent stem (iPS) cells, derived directly from the patient. But iPS cells have limitations, especially regarding the disease of the recipient and possible difficulties to handle or prepare autologous iPS cells. Finally, reaching standards of good clinical or manufacturing practices could be challenging. That is why well-characterized and universal hPS cells could be a better solution. In this review, we will discuss the interest and the feasibility to establish hPS cells bank, as well as some economics and ethical issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · cited 1×
“Because it has been demonstrated that hPS cells expressed low level of HLA-I [26, 32], these cells are therefore excellent targets for NK cells [33].”
BackgroundHematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Adipose-derived stem cells for regenerative medicine
Gimble, J. M., Katz, A. J., & Bunnell, B. A. (2007) · Circulation Research · doi:10.1161/01.res.0000265074.83288.09 · Cited by 2,332 · cited 1×
“They can also be found in other tissues, such as adipose tissue [7], the dental pulp [8], themammary gland [9], the olfactory mucosa [10], and the neural tissue [11].”
BackgroundSomatic coding mutations in human induced pluripotent stem cells
Gore, A., Li, Z., Fung, H.-L., Young, J. E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., Giorgetti, A., Israel, M. A., Kiskinis, E., et al. (2011) · Nature · doi:10.1038/nature09805 · Cited by 1,273
Generation of induced pluripotent stem cells from human blood
Loh, Y.-H., Agarwal, S., Park, I.-H., Urbach, A., Huo, H., Heffner, G. C., Kim, K., Miller, J. D., Ng, K., & Daley, G. Q. (2009) · Blood · doi:10.1182/blood-2009-02-204800 · Cited by 626
Taylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A., & Bolton, E. M. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.07.014 · Cited by 428 · cited 1×
“The establishment of a clinical grade bank of homozygous cell lines, which can be expanded and differentiated for a large number of patients, would be more coherent [25].”
BackgroundDrukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0188 · Cited by 402 · cited 5×
“The killing mechanism of CD8+Tcells is mediated by the presentation of the antigen to the T-cell receptor, and NK cells kill the target cells expressing low level or no HLA-I.”
BackgroundInfluentialNakajima, F., Tokunaga, K., & Nakatsuji, N. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0566 · Cited by 168 · cited 1×
“[23] both answered this question for their own countries, United Kingdom and Japan, respectively.”
Background
Cited by
Non-syndromic retinitis pigmentosa
Verbakel, S. K., van Huet, R. A. C., Boon, C. J. F., den Hollander, A. I., Collin, R. W. J., Klaver, C. C. W., Hoyng, C. B., Roepman, R., & Klevering, B. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.005 · Cited by 973
Generation of hypoimmunogenic human pluripotent stem cells
Han, X., Wang, M., Duan, S., Franco, P. J., Kenty, J. H.-R., Hedrick, P., Xia, Y., Allen, A., Ferreira, L. M. R., Strominger, J. L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902566116 · Cited by 363
Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications
Yoshihara, M., Hayashizaki, Y., & Murakawa, Y. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9680-6 · Cited by 283
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Making it personal: The prospects for autologous pluripotent stem cell-derived therapies
Blair, N. F., & Barker, R. A. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0057 · Cited by 22
Metadata
- Authors
- de Rham, C., & Villard, J.
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-6
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- OpenAlex
- W2117804155
- Cited by
- 96
- References
- 8
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.